Dental Tribune Middle East & Africa Edition

Using a bone-creating protein to augment the maxillary sinus could improve dental implant success, according to Georgia Health Sciences University re- searchers. Dental implants, screws that anchor permanent prosthetic teeth, won’t work if the bone in which they are anchored is too thin. Bone-thinning is a common cause and consequence follow- ing tooth loss. The current fa- vored solution is to supplement theareawithbonegraftstostabi- lize the implant base. But that technique is problematic “pri- marily because it involves addi- tional surgeries to harvest the bone,” said Dr. Ulf M.E. Wikesjö, Interim Associate Dean for Re- search and Enterprise in the GHSU College of Dental Medi- cine. In animal studies, he and his team at the GHSU Laboratory for Applied Periodontal & Craniofa- cial Regeneration found that im- planting bone morphogenetic protein in the sinus more new bone will form within four weeks than using conventional bone grafting at the same site. “We found that BMP induced superior bone quality over that following bone grafts, which im- provesthechancesforsuccessful implants,” Wikesjö said . “BMP is phenomenal, because it’s a true, off-the-shelfproductwitheaseof use that can produce real results, and it could be the new gold stan- dard for this procedure.” According to the American Association of Oral and Maxillo- facial Surgeons, 69 percent of adults ages 35-44 have lost at least one tooth due to decay, dis- ease or trauma, and 26 percent of adults have lost all permanent teethbyage74.Beforedentalim- plants were available, the only options for replacing these miss- ing teeth were dentures and den- tal bridges, both of which could lead to further bone loss. Im- plants provide patients with nu- merous benefits, including im- proved oral health, appearance, speech, convenience, durability and ability to eat. DT Protein Could Improve Dental Implants DENTALTRIBUNE Middle East & Africa Edition News & Opinions 5 I m p l a n t S y s t e m Dentoflex goes beyondDentoflex goes beyond Dentoflex has been operating in the dental market for over three decades and doesn’t stop reinventing itself. The company is moving in the right direction by aiming to develop on a daily basis, invest in the latest technology and expand into new horizons. Dentoflex has an ambition to break down and overcome any barriers and form strong relationships and alliances in countries worldwide. For more than 30 years, Dentoflex has been creating healthy and attractive smiles in Brazil, and is now growing all over the world. The Dentoflex’s surface treatments includes aluminum oxide blasting, followed by acid passivation which combines texture and perfect porosity for an excellent biological effect, and as a result giving conditions for osseointegration and clinical success. The Dentoflex implants offer a more rougher surface of up to 300 times greater than a machined surface, stabalising bone-implant contact by up to six times. Treatment SurfaceTreatment Surface BRANCH OFICCE: JAFZA VIEW - LOB 19 OFFICE 1301 - P.O. BOX 261901 - DUBAI - U.A.E TEL: +971 (0) 48855404 EXT: 304/305 - FAX:+971 (0) 48855405 MOB: +971 (0) 559250844 comex@dentoflex.com.br www.dentoflex.com.br AD Daniel Zimmermann DTI LONDON,UK/NEWYORK,USA/ LEIPZIG, Germany: DENTSPLY has entered into a co-branding agreementwithGlaxoSmithKline, aglobalhealth-caremanufacturer based in the UK. According to a pressnotereleasedinJanuary,the deal will allow the US company to combine its NUPRO in-office pro- phylaxis range with Sensodyne, GSK’s specialist toothpaste brand forpatientssufferingfromdentine hypersensitivity. According to the companies, no exchange of cash orequitybyeitherpartyisinvolved in the agreement. NUPRO, which consists of pro- phy and polishing pastes, is based on NovaMin, a technology ac- quiredbyGSKthroughamulti-mil- lion dollar purchase in 2009. The formula contains calcium sodium phosphosilicate, a synthetic min- eral found to seal dentinal tubules, themainreasonforhypersensitive teeth. GSK currentlyuses the same technology in its heavily marketed Sensodyne toothpaste brand. Carlton Lawson, Vice-Presi- dent of Sensodyne, GSK, said that by utilising both companies’ brands and capabilities, his com- pany aims to build awareness of the benefits of NovaMin and fur- ther consolidate its position as the leaderintheover-the-counteroral health-care market. According to the company, 90 per cent of its worldwide rev- enueisearnedthroughtoothpaste sales. The company also claims to have a global market share of almost 10 per cent. DT GSK and DENTSPLY cooperate in oral health